Pci Biotech Holding Asa · LSE:0JGL
Pci Biotech Holding Asa — Q4 2022 Earnings Presentation
19 slides from Pci Biotech Holding Asa's earnings presentation, Feb 17, 2023
Slide 1: PCI Biotech - Q4 2022 Interim Report
PCI Biotech - Enabling intracellular Q4 2022 Interim Report delivery Presentation February 17, 2023 Ronny Skuggedal, CEO / CFO Anders Høgset, CSO Morten Luhr, BD Manager www.pcibiotech.com
Slide 2: Q&A session through teleconference and webcast console
PCI Biotech Q&A session through teleconference and webcast console This presentation will also be presented through a teleconference, mainly facilitated for attendees intending to ask questions verbally during the Q&A session. If you plan to use this facility, please join the event 5-10 minutes prio
Slide 3: Important notice and disclaimer
PCI Biotech Important notice and disclaimer This presentation may contain certain forward-looking Factors that could cause these differences include, but are not limited to, statements and forecasts based on uncertainty, since they implementation of PCI Biotech’s strategy and its ability to further
Slide 4: Table of Contents
Table of Contents Highlights Operational review Key financials Outlook Q&A www.pcibiotech.com 4
Slide 5: Highlights Q4 2022 - fimaNAC
Highlights Q4 2022 fimaNAC Demonstrate fimaNAC-mediated nucleic acid delivery for dermatology Dermatology First step for the discovery project planned in a wound model Bioprocessing • External feasibility study on track, expected readout 1H 2023 • Positive results may trigger collaborative devel
Slide 6: Highlights Q4 2022 - fimaVACC
Highlights Q4 2022 fimaVACC ► Exploring approaches aiming to identify novel immunotherapy combinations Intratumoural A patent application for an undisclosed treatment approach planned to be filed Q1 2023 immunotherapy Ph.D. candidate grant of up to NOK 2.5 million over 3 years, commencing Q1 202
Slide 7: Highlights Q4 2022 - Corporate
Highlights Q4 2022 Corporate Estimated financial runway extended towards end of 2024, with current plans Estimated remaining cash effect for the RELEASE trial closure is less than NOK -1 million Downsizing, reported Q3, was enacted during 2H-22 with full cost reduction effect in Q1 2023 Cash
Slide 8: Operational review
Operational review 8
Slide 9: fimaNAC: Platform technology for delivery of nucleic acids to skin
Platform technology for delivery of nucleic acids to skin fimaNAC Background Operational Many skin conditions with large unmet medical needs can potentially be treated with nucleic acid based therapies review – E.g. chronic ulcers, inflammatory diseases, inherited diseases Dermatology Many app
Slide 10: Demonstrating topical delivery of mRNA in wound model
Demonstrating topical delivery of mRNA in wound model fimaNAC - Performed by a leading CRO Study builds on previous results where fimaNAc demonstrated 30x enhanced mRNA delivery by Operational intradermal injection review – Novel, topical approach: mRNA and fimaporfin applied to wound, followed
Slide 11: fimaNAC Dermatology – further plans
fimaNAC Dermatology – further plans Use data from first phase for early-stage partnering Operational Show effect in wound healing model, i.e. that fimaNAc treatment accelerates healing of wounds review – with partner’s nucleic acid molecule Dermatology Alternatively - continue preclinical plat
Slide 12: Maximising yield in gene therapy manufacturing
fimaNAC Maximising yield in gene therapy manufacturing Operational review – Bioprocessing Cells in culture Gene edit and expand Harvest • Cell lines • Nucleic acids • Quantity of material • Range in quantity • Enzymes • Purity of material • Growth factors • Quality of material www.pcibiotech.com 12
Slide 13: Maximising yield in gene therapy manufacturing
fimaNAC Maximising yield in gene therapy manufacturing Operational review – Bioprocessing • Patent submitted 2022 • Positive initial external feedback • 1H-23 will be focussed on proof-of-principle data • Interest for prototype testing, pending in vitro data www.pcibiotech.com 13
Slide 14: fimaVACC: Intratumoural immunotherapy – treat locally, act globally
fimaVACC Intratumoural immunotherapy: “Treat locally – act globally” ► Most patients do not respond properly to current cancer immunotherapies ► New combination therapies can improve response rates, but are hampered by side effects Operational review – Intratumoural immunotherapy ► Induction of an i
Slide 15: fimaVACC strongly improves effect of intratumoural immunotherapy
fimaVACC fimaVACC strongly improves effect of clinically explored intratumoural immunotherapy (IT) Operational review – fimaVACC retards tumour Intratumoural immunotherapy fimaVACC improves animal growth survival 1200 120 Untreated IT without 1000 control 100 tumour volume (mm3) PCI ► Seek patent pr
Slide 16: Key financials, Outlook, Q&A
Key financials Outlook Q&A 16
Slide 17: Finance: Key financial figures
Finance ► Financial run-way estimate extended towards the end of 2024 Providing an opportunity window to demonstrate the commercial potential of the platform RELEASE closure, and organisational changes with full cost reduction effect in Q1 2023 Key financial Other income, current SkatteFUNN gr
Slide 18: Outlook: 1H 2023 Milestones
Outlook Leveraging the PCI technology platform within dermatology, bioprocessing, and immunotherapy Enabling intracellular delivery 1H 2023 Milestones 1H 2023 Milestones • Data readout from topical nucleic acid delivery Laying the ground for • Advance viral manufacturing application • Submit patent
Slide 19: PCI Biotech - For enquiries
Enabling intracellular PCI Biotech delivery For enquiries: Ronny Skuggedal, CEO / CFO Mobile phone: +47 940 05 757 E-mail: rs@pcibiotech.com www.pcibiotech.com 19